

## Contents

### Part I Introduction 1

- 1 Chronology of Drug Development for Malaria 3**  
*Nalini Kurup and Nikhil Rajnani*
- 1.1 Introduction 3
- 1.1.1 Life Cycle of Malaria (Adapted from CDC) 4
- 1.2 Malaria – Erstwhile Memories 5
- 1.2.1 Progress Fighting Malaria 5
- 1.3 Current Chemotherapy Used to Treat Malaria 7
- 1.3.1 Current Combination Therapy 13
- 1.4 Drug Resistance of Antimalarial Drugs 14
- 1.4.1 Detection of Drug Resistance 16
- 1.5 Newer Drugs Approved for Malaria Treatment 17
- 1.6 Current Approaches to Developing a Malaria Vaccine 18
- 1.6.1 Hope for Vaccine Lies in the Parasite Itself 18
- 1.7 Conclusion: The Path Forward 20
- 1.7.1 RTS, -S Vaccine: A New Tool with Potential for Africa 20
- References 21

### Part II Challenges and Opportunities in Malaria Therapy 25

- 2 Scientific Challenges and Treatment Opportunities in the Face  
of Shifting Malaria Epidemiology 27**  
*Ketaki Ramani*
- 2.1 Introduction 27
- 2.2 The Scientific Challenges Against Malarial Drug 28
- 2.3 Advances in Understanding and Managing Drug Resistance 29
- 2.3.1 Vector and Its Control 29
- 2.3.2 Parasite and Its Control 30
- 2.3.2.1 Malaria Vaccine 31
- 2.3.2.2 Antimalarial Drugs 31

2.4	Methods to Assess the Presence and Level of Drug Resistance	32
2.4.1	Therapeutic Efficacy of Antimalarial Drugs	32
2.4.2	Molecular Markers Associated with <i>P. falciparum</i>	33
2.5	Antimalarial Drugs Currently in Use and in the Pipeline	33
2.6	Future	38
	References	40

### 3 Emerging Formulation Technologies Against Malaria

#### Resurgence 45

*Kinjal Parikh, Rakhee Kapadia, Rohan Pai, Mahendra Prajapati, and Ganesh Shevalkar*

List of Abbreviations 45

3.1	Introduction	46
3.1.1	Major Pathological Hallmarks of Malaria	46
3.1.2	Current Treatment Strategies	47
3.2	Pitfalls of the Current Treatment Regimen	47
3.2.1	Drug Resistance	47
3.2.2	High Drug Dose	48
3.2.3	Long-Term Treatment	48
3.2.4	Recurrence and Reversion of Diseases	48
3.3	Nanotechnology-Based Strategies for Targeting in Antimalarial Therapy	49
3.3.1	Passive Targeting	49
3.3.2	Active Targeting	49
3.3.2.1	Hepatocyte Targeting	50
3.3.2.2	Erythrocyte Targeting	50
3.3.2.3	Brain Targeting	50
3.3.3	Rapid Diagnosis and Vector Control	51
3.4	Nano Formulations for Malarial Treatment	51
3.4.1	Lipid-Based Nanoplatfoms	52
3.4.1.1	Nanoemulsion	52
3.4.1.2	Self-Emulsifying Drug Delivery System (SEDDS)	53
3.4.1.3	Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs)	54
3.4.1.4	Liposome	54
3.4.2	Polymer-Based Nanoplatfoms for Malaria	55
3.4.2.1	Nanoparticles	55
3.4.2.2	Nanocapsules	58
3.4.2.3	Dendrimers	58
3.4.2.4	Micelles	59
3.4.2.5	Polymeric Hydrogel Nanoparticles	59
3.4.2.6	Nanosuspension	59
3.4.3	Organized Layer-by-Layer Assembly	59
3.4.4	Inorganic Nano-architectonics	59
3.4.4.1	Metallic Platforms	60

3.4.4.2	Quantum Dots	61
3.4.4.3	Carbon Nanostructures	62
3.4.4.4	Bio-ceramics	62
3.4.5	Bio-inspired Nanocarriers	63
3.4.5.1	Vaccines Based on Bio-inspired Nanocarriers	63
3.4.5.2	Bio-engineered Strategy Based on Erythrocytes	64
3.4.6	Protein–Peptide-Based Drug Delivery System	64
3.4.7	Stimuli-Responsive Platforms for Malaria	64
3.4.7.1	pH-Responsive Formulations	65
3.4.7.2	Thermo-Responsive Formulations	65
3.4.7.3	Redox State Responsive Substances	65
3.4.7.4	Stimuli-Responsive Liquid Crystalline Materials	65
3.5	Diagnostics	66
3.5.1	Stimuli-Responsive Iron Oxide and Gold Nanoparticle Reagent System	66
3.5.2	Immunological Adjuvants	66
3.5.3	Nanofibers	66
3.6	Challenges in Clinical Translation of Nanomedicine	67
3.6.1	Biological Challenges	67
3.6.2	Biocompatibility and Safety	67
3.6.3	Challenges in Manufacturing Scale-Up and Reproducibility	67
3.6.4	Analytical Characterization and Quality Control Challenges of Nano-Formulations	68
3.6.5	Regulatory Challenges	68
3.6.6	Other Challenges	69
3.7	Summary and Future Perspective	69
3.8	Conclusion	69
	Acknowledgments	70
	References	70
<b>4</b>	<b>Targeted Drug Delivery for Antimalarial Therapy</b>	<b>83</b>
	<i>Suha Zwayen, Tamara Zwain, and Kamalinder K. Singh</i>	
4.1	Introduction	83
4.2	Remodelling of Parasite-Infected Red Blood Cell (pRBC)	84
4.2.1	The Red Blood Cell Membrane (RBCM)	85
4.2.2	The Parasitophorous Vacuole Membrane (PVM)	85
4.2.3	The Parasite Plasma Membrane (PPM)	86
4.3	The Emergence of Resistance and Antimalarial Therapy Approach	86
4.4	Nanocarriers for Antimalarial Drug Delivery	89
4.4.1	Liposomes	89
4.4.2	Solid Lipid Nanoparticles (SLNs)	91
4.4.3	Nanostructured Lipid Carriers (NLCs)	91
4.4.4	Nano-emulsions (NEs)	91
4.4.5	Polymeric Nanoparticles	92
4.5	Targeted Antimalarial Drug Delivery Systems	92

- 4.5.1 Passive Drug Targeting with Conventional Nanocarriers 92
- 4.5.2 Active Drug Targeting with Surface-Modified Nanocarrier 93
- 4.6 Conclusion: Moving Towards the Future 97
- Acknowledgements 97
- References 97
  
- 5 The Imminent Threat of Antimalarial Drug Resistance 105**  
*Bharti Singal and Jyoti Chhibber-Goel*
- 5.1 Introduction 105
- 5.2 Antimalarial Drugs: An Overview 107
- 5.3 The Evolution of CQ Resistance 109
  - 5.3.1 Mechanism of Action of CQ 109
  - 5.3.2 Basis of CQ Resistance 110
  - 5.3.3 Prevalence of CQ Resistance 112
  - 5.3.4 WHO Guidelines to Use CQ 113
- 5.4 Impact of Sulfadoxine–Pyrimethamine Resistance 113
  - 5.4.1 Mechanism of Action of SP 114
  - 5.4.2 SP Resistance 116
  - 5.4.3 Distribution of DHPS and DHFR Mutation Across Globe 117
    - 5.4.3.1 *dhfr* 117
    - 5.4.3.2 *dhps* 117
  - 5.4.4 WHO Guidelines to Use SP 118
    - 5.4.4.1 IPTp Guidelines 118
    - 5.4.4.2 IPTi Guidelines 118
- 5.5 ACT Resistance 118
  - 5.5.1 Mechanism of Action of ART 121
  - 5.5.2 ART Resistance and ACT Failure 122
  - 5.5.3 WHO Guidelines 123
- 5.6 Conclusion: The Road Ahead 124
- References 124
  
- 6 Current Therapies and New Drug Targets for the Future Drug Development of Drug Resistant Malaria 133**  
*Pooja Mittal and Rupesh K. Gautam*
- 6.1 Introduction 133
- 6.2 Life Cycle of *Plasmodium falciparum* 134
- 6.3 Current Antimalarial Therapy and Their Shortcomings 134
- 6.4 Drug Targets for Current Antimalarial Therapy 136
  - 6.4.1 Drug-Resistant Malaria and Identification of New Targets 137
    - 6.4.1.1 Food Vacuole as Drug Targets 137
    - 6.4.1.2 Shikimic Acid Pathway Targeting 142
    - 6.4.1.3 Targeting Folate Pathway and Methionine Synthesis Pathway 142
    - 6.4.1.4 Glycolytic Pathway Inhibition 144
  - 6.4.2 Mitochondria as Drug Targets 144

- 6.4.2.1 Targeting Electron Transport Chain 144
- 6.4.2.2 Inhibition of Dihydroorate Dehydrogenase 144
- 6.5 Future Drug Development for the Treatment of Malaria 146
  - 6.5.1 Benefits of Nanocarriers 146
  - 6.5.2 Lipid-Based Drug Delivery 146
  - 6.5.3 Liposomes (as Nanocarriers) 146
  - 6.5.4 Nanostructured Lipid Carriers 146
  - 6.5.5 Solid Lipid Nanocarriers 147
- 6.6 Conclusion 147
- References 147

### Part III Drug Development 151

- 7 Assays for Antimalarial Drug Discovery 153**  
*Varun Gorki, Neha S. Walter, and Sukhbir Kaur*
  - 7.1 Introduction 153
  - 7.2 *In Vitro* Assays for Antimalarial Drug Discovery 155
    - 7.2.1 Schizont Maturation Inhibition Assay (Microscopic Test) 156
    - 7.2.2 *In Vitro* Micro Test Technique 156
    - 7.2.3 Radioisotope Assay 156
    - 7.2.4 Colorimetric Assay (Plasmodium Lactate Dehydrogenase Assay [pLDH]) 157
    - 7.2.5 ELISA-Based Methods 157
      - 7.2.5.1 DELI Assay 157
      - 7.2.5.2 Assay Based on Histidine-Rich Protein II (HRP II) of *P. falciparum* 158
    - 7.2.6 Flow Cytometry 158
    - 7.2.7 Fluorometric Assay 158
    - 7.2.8  $\beta$ -Hematin Formation (Haemozoin Test) 159
    - 7.2.9 Drug Interaction Assay and Isobologram Analysis 159
    - 7.2.10 PCR-Based Methods 160
    - 7.2.11 *In Vitro* Assays Targeting Exo-erythrocytic and Sexual Stages of the Parasite 160
      - 7.2.11.1 Exo-erythrocytic Schizontocidal Assay 160
      - 7.2.11.2 Ex-flagellation Assay 160
  - 7.3 *In Vivo* Assays for Antimalarial Drug Discovery 161
    - 7.3.1 Peters' 4-Day Test 162
    - 7.3.2 Dose Ranging Full 4-Day Test 163
    - 7.3.3 Onset/Recrudescence Test 163
    - 7.3.4 Preventive Test 166
    - 7.3.5 Curative Test 166
    - 7.3.6 Hill's Test for Causal Prophylaxis and Residual Activity 166
    - 7.3.7 Assays with *P. berghei* Green Fluorescent Protein (PbGFP) 167
    - 7.3.8 Assays Employing Immunocompromised Mice 167

7.3.9	Primate Models for <i>In Vivo</i> Studies	168
7.3.10	Sporontocidal Assays	169
7.3.11	Anti-sporozoite Assay	169
7.4	<i>Ex Vivo</i> Assays for Antimalarial Drug Discovery	169
7.5	Assays for Assessment of <i>In Vitro</i> Toxicity	170
7.5.1	MTT Assay	170
7.5.2	XTT Assay	172
7.5.3	LDH (Lactate Dehydrogenase) Assay	172
7.5.4	Protein Content Assay	173
7.5.5	Neutral Red Uptake Assay (NRU)	173
7.6	Assays for Assessment of <i>In Vivo</i> Toxicity	173
7.6.1	Acute Toxicity	174
7.6.1.1	Limit Test of Lorke	175
7.6.1.2	Up and Down Procedure	175
7.6.2	Chronic Toxicity	175
7.7	Conclusion	176
	References	177
<b>8</b>	<b>Aminoacyl-tRNA Synthetases as Malarial Drug Targets: A Structural Biology Perspective</b>	<b>187</b>
	<i>Bharti Singal and Jyoti Chhibber-Goel</i>	
8.1	Introduction	187
8.2	<i>Pf/Pv</i> -aaRSs	188
8.2.1	<i>Pf/Pv</i> Genome	188
8.2.2	Aminoacyl-tRNA Synthetases (aaRSs)	189
8.3	Aminoacyl-tRNA Synthetases as Druggable Targets	190
8.4	Biochemical Screening of Drug Libraries	192
8.4.1	Colorimetric Assays	192
8.4.2	Enzyme-Coupled Assays	193
8.4.3	Luciferase Assay	193
8.4.4	Assay to Test Synthetic as Well as Proofreading Activity	193
8.5	Structurally Validated <i>Pf/Pv</i> -aaRSs as Drug Targets	194
8.5.1	Lysyl-tRNA Synthetase (KRS)	194
8.5.2	Prolyl-tRNA Synthetase	197
8.6	Potential Drug Targets <i>Pf/Pv</i> -aaRSs	199
8.6.1	Leucyl-tRNA Synthetase (LRS)	199
8.7	Arginyl-tRNA Synthetase (RRS)	199
8.7.1	Tryptophanyl-tRNA Synthetase (WRS)	201
8.7.2	Tyrosyl-tRNA Synthetase	202
8.8	Others	203
8.9	Conclusion: The Road Ahead	203
	References	204

- 9 Natural Products as a Source for Antimalarial Drug Development Process – An Overview 213**  
*Uma R. Lal and Snigdha Lal*
- 9.1 Introduction 213
- 9.2 Phytochemicals as Antimalarial Agents: Recent Developments 214
- 9.2.1 Alkaloids 214
- 9.2.2 Terpenes 219
- 9.2.2.1 Sesquiterpene Lactones 219
- 9.2.2.2 Diterpenes 220
- 9.2.2.3 Triterpenes 222
- 9.2.2.4 Steroids and Others 224
- 9.2.3 Polyphenols 224
- 9.2.3.1 Biflavonoids 224
- 9.2.3.2 Prenylated Flavonoids 226
- 9.2.3.3 Other Flavonoids 226
- 9.3 Traditional System of Medicine and Malaria 227
- 9.3.1 Plants/Formulations Used in Malaria Treatment in Ayurvedic System of Medicine 227
- 9.4 Conclusions 228
- References 228
- 10 Mushroom-Derived Products as an Alternative Antimalarial Therapeutics: A Review 235**  
*Senzosenkosi S. Mkhize, Kgothatso E. Machaba, Mthokozisi B. C. Simelane, and Ofentse J. Pooe*
- 10.1 Introduction 235
- 10.2 Biological Roles of Mushrooms 235
- 10.2.1 Malarial History and Impact 235
- 10.2.2 Antimalarial Activity of Mushroom Extracts 237
- 10.2.3 Bioactive Molecules Found Within Mushrooms 239
- 10.2.4 Phytochemical Properties of Mushroom Derived Antimalarial Products 241
- 10.2.5 Immunomodulatory Properties of Mushrooms 243
- 10.3 Conclusion 243
- Acknowledgements 244
- References 244
- 11 Discovery and Trends of 8-Aminoquinoline and 4-Aminoquinoline Classes of Antimalarials 251**  
*Meenakshi Jain, Samarpita Das, and Rahul Jain*
- 11.1 Introduction 251
- 11.1.1 History 251

- 11.1.2 Mode of Action 253
- 11.1.3 SAR of Aminoquinolines 255
  - 11.1.3.1 SAR of 8-Aminoquinolines 255
  - 11.1.3.2 SAR of 4-Aminoquinolines 257
- 11.2 Synthetic Approaches of 8-Aminoquinolines and 4-Aminoquinolines 259
  - 11.2.1 Synthetic Approach of 8-Aminoquinolines 259
    - 11.2.1.1 Synthetic Approach of Well-Established Drugs 259
    - 11.2.1.2 Synthetic Approach of Recently Developed PQ Congeners 269
  - 11.2.2 Synthetic Approaches of 4-Aminoquinolines 270
    - 11.2.2.1 Synthetic Approaches to Well-Established Drugs 270
    - 11.2.2.2 Synthetic Approach of PQ–CQ Hybrid 280
- 11.3 Conclusion and Future Perspectives 280
  - Acknowledgment 281
  - References 281
- 12 Antimalarial Activity of Novel Class of 1,3-Benzoxaborole Derivatives Containing 1,3,4-Oxadiazole Moiety 285**  
*Vinayak Adimule, Adarsha Haramballi Jagadeesha Gowda, Santosh S. Nandi, and Debdas Bowmik*
  - 12.1 Introduction 285
    - 12.1.1 Materials and Methods 286
    - 12.1.2 Synthesis 287
  - 12.2 Experimental Procedure for *In Vitro* Studies on Antimalarial Activity 287
    - 12.2.1 Experimentation 289
      - 12.2.1.1 Analytical Results of the Intermediate Compounds (**6a–10a**) 289
  - 12.3 Analytical Results of Intermediate Compounds (**12–16**) 290
    - 12.3.1 NMR and CMR Analysis 290
  - 12.4 Synthesis Procedures for 4-Ethoxy Phenyl Boronic Acid (General Procedure for Compounds **2**, **3**, and **4**) 292
    - 12.4.1 Synthesis of 1-Bromo-4-(Cyclopropyl Methyl) Benzene (Compound **2**) 292
      - 12.4.1.1 1-Bromo-4-(Cyclopentyl Methoxy)Benzene (Compound **2b**) 292
      - 12.4.1.2 1-Bromo-4-(Cyclohexyl Methoxy)Benzene (Compound **2c**) 292
      - 12.4.1.3 1-(Benzyloxy)-4-Bromobenzene (Compound **2d**) 293
      - 12.4.1.4 1-Bromo-4-(Pentyloxy) Benzene (Compound **2e**) 293
      - 12.4.1.5 Synthesis of 4-Methoxy Phenyl-Bispinacolato Adduct (**3a**) 293
      - 12.4.1.6 Synthesis of 4-Methoxy Phenyl Boronic Acid 293
      - 12.4.1.7 General Procedure for the Synthesis of Derivatives (Compounds **6–10**) (Step II) 293
      - 12.4.1.8 General Procedure for the Synthesis of Derivatives (Compounds **6a–10a**) 293
      - 12.4.1.9 General Procedure for the Synthesis of Derivatives (Compounds **12–16**) 294



- 12.5 Results and Discussion 294
- 12.5.1 *In Vitro* Antiplasmodial Activity 294
- 12.6 Conclusion 297
- Authors Contributions 298
- Acknowledgments 298
- Conflict of Interest 298
- References 298

## **Part IV A Vaccine Perspective 303**

- 13 Recent Advances in Malaria Vaccine Development 305**  
*Sailendra Kumar Mahanta*
- 13.1 Introduction 305
- 13.2 History of Malaria Vaccine Development 306
- 13.3 Vaccine Design Targets and Approaches 308
- 13.4 Types of Malaria Vaccine 309
- 13.4.1 Pre-erythrocytic Vaccines 309
- 13.4.1.1 Vaccines Based on the RTS, -S, and CSP Encoded Sections of the Malaria Gene 310
- 13.4.2 Whole Sporozoite Vaccines 311
- 13.4.3 Blood Stage Vaccines (BSVs) 311
- 13.4.4 Placental Malaria Vaccines 312
- 13.4.5 Transmission Blocking Vaccines (TBV) 313
- 13.4.6 Vaccines for *P. vivax* 314
- 13.5 Conclusions 314
- References 314
- 14 Toll-Like Receptor-Based Adjuvants: A Gateway Toward Improved Malaria Vaccination 319**  
*Deepika Kannan, Arshpreet Kaur, Deepak B. Salunke, and Shailja Singh*
- 14.1 Introduction 319
- 14.2 Host Immunological Responses in Malaria Conferring Protection 322
- 14.2.1 Innate Immunity 322
- 14.2.2 Adaptive Immunity 324
- 14.3 Crosstalk of PRRs in Host Immune System with Malarial Antigens 326
- 14.3.1 Glycosyl Phosphatidylinositols (GPI) 328
- 14.3.2 Plasmodial RNA 330
- 14.3.3 Hemozoin (Hz) 330
- 14.4 Synthetic TLR Adjuvants: An Approach to Enhance Vaccine Immunogenicity 331
- 14.4.1 TLR2 331
- 14.4.2 TLR4 333
- 14.4.3 TLR5 336
- 14.4.4 TLR7/8 337

14.4.5	TLR9	339
14.5	Conclusion	341
	Abbreviations	341
	References	342
<b>15</b>	<b>Pure TLR7 Agonistic BBIQ is a Potential Adjuvant Against <i>Plasmodium berghei</i> ANKA Challenge <i>In Vivo</i></b>	<b>353</b>
	<i>Ruchika Saroa, Deepender Kaushik, Aruna Rakha, Upma Bagai, Sukhbir Kaur, and Deepak B. Salunke</i>	
15.1	Introduction	353
15.2	Material and Methods	354
15.2.1	Experimental Animals	354
15.2.2	Ethical Clearance	355
15.2.3	Parasite Infection	355
15.2.4	Isolation of Blood Stage Fraction	355
15.2.5	Adjuvant	355
15.3	Immunisation Protocol and Post-challenge Regime	356
15.4	Study Design	357
15.5	Isolation of Splenic Lymphocytes from Mice	357
15.6	FACS Analysis of Isolated Lymphocytes	357
15.7	IgG1 and IgG2a Antibody Response	357
15.8	Estimation of Various Cytokines	358
15.9	Statistical Analysis	358
15.10	Results and Discussion	358
15.10.1	Course of Infection	358
15.10.2	Flow Cytometric Analysis of Splenic T Cells and T reg Cells	358
15.10.3	Cytokine Profiling	360
15.10.4	Flow Cytometric Analysis of Splenic B Cells	362
15.10.5	IgG1 and IgG2a Response	362
15.11	Conclusion	363
	Conflict of Interests	364
	Funding	364
	Acknowledgment	364
	References	364
	<b>Index</b>	<b>367</b>